In addition, Pexa-Vec is being evaluated in a Phase I/II trial in patients with treatment-refractory colorectal cancer as monotherapy and in combination with irinotecan, and in a Phase IIa trial in treatment-refractory kidney cancer patients

Cancer Research UK licensed data from its Phase II study of rucaparib (AG014699) in breast and ovarian cancer patients with known BRCA 1 or 2 mutations to Clovis Oncology Inc., of Boulder, Colo., in return for undisclosed licensing fees

Amgen Inc., of Thousand Oaks, Calif., said the Phase III head-to-head ASPECCT ('763) trial evaluating its Vectibix (panitumumab) vs. Erbitux (cetuximab, Eli Lilly and Co.) as a single agent for the treatment of chemorefractory metastatic colorectal cancer in patients with wild-type KRAS tumors (n = 1 ,010) met its primary endpoint of noninferiority for overall survival...The studies are evaluating the onset and incidence of OM in head and neck cancer patients undergoing chemo and radiation therapy

The immunotherapy drug, called ETBX-011, induced an immune response in advanced colorectal cancer patients and gave encouraging overall survival results

The product, a small molecule that binds to S100A9, is the subject of a study across 37 countries in 1,245 metastatic castrate-resistant prostate cancer patients who have not yet received chemotherapy

The Phase II study is designed to evaluate whether the combination of MM-121 with paclitaxel is more effective than treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen in two patient groups of HER2-negative, locally advanced breast cancer patients

Viralytics Ltd., of Sydney, Australia, said it finalized the clinical study report on the Phase I evaluation of Cavatak, administered intravenously to late-stage melanoma, prostate, breast or colorectal cancer patients, with results showing that the oncolytic virus-based drug candidate was well tolerated, with some evidence of stable disease despite most patients only receiving a single dose

Soligenix Inc., of Princeton, N.J., said the FDA cleared the first to start a Phase II trial of SGX942, an innate defense regulator, for the treatment of oral mucositis resulting from radiation and/or chemotherapy treatment in head and neck cancer patients

Ohr Pharmaceutical Inc., of New York, said a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia did not meet the primary endpoint of weight gain, but the 18 patients who completed the treatment protocol achieved stable body weight, body fat and muscle mass with a significant increase in appetite (p = 0.001

Prima BioMed Ltd., of Sydney, Australia, said it started recruiting patients in its CANVAS (CANcer VAccine Study) Phase II/III trial in Europe to test CVac for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer in patients who achieve remission after optimal debulking surgery and standard first-line chemotherapy

Data showed antitumor activity of the drug in a heavily pre-treated and advanced patient population, including a complete response in an endometrial cancer patient who had multiple hepatic metasteses

TapImmune Inc., of Seattle, said an interim safety analysis of the first five breast cancer patients treated with HER2/neu Class II antigens did not show any serious adverse events, so treatment of the remaining 17 patients in the Phase I study at the Mayo Clinic will progress

Immunovaccine Inc., of Halifax, Nova Scotia, reported results from a Phase I study showing that all ovarian cancer patients receiving cancer vaccine DPX-Survivac who were evaluable by tetramer staining produced survivin-specific CD8 T cells following one or two vaccinations...The Phase Ib portion will enroll all patients with solid tumors, while the Phase IIa portion will enroll gastric and breast cancer patients

GTx Inc., of Memphis, Tenn., attained its enrollment goal for both of its pivotal Phase III studies of enobosarm to prevent and treat muscle wasting in non-small-cell lung cancer patients

The authors concluded that in the study the combination of brostallicin and cisplatin showed promising activity in heavily pretreated metastatic triple-negative breast cancer patients and achieved its primary endpoint comparing favorably to other Phase II trials in that disease

The four-week, repeat-dose study is designed to investigate the hypothesis that inhibition of hepcidin can raise hemoglobin levels in cancer patients with anemia

Precision Therapeutics Inc., of Pittsburgh, presented study results at the International Gynecologic Cancer Society meeting in Vancouver, British Columbia, comparing ChemoFx results in optimally and suboptimally debulked primary ovarian cancer patients

Galena Biopharma Inc., of Lake Oswego, Ore., said data from a Phase I/II study showed that NeuVax (nelipepimut-S or E75) decreased circulating tumor cells in 16 of 26 breast cancer patients during vaccine treatment

GTx Inc., of Memphis, Tenn., said it will present data later this month at the International Society of Geriatric Oncology meeting in Manchester, UK, from its Phase IIb trial of enobosarm improved physical function in cancer patients with muscle wasting